Who are AXS-07's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sumatriptan Succinate Oral Tablet, Migranal nasal spray at 1 hour, Migranal nasal spray at 4 hour, sumatriptan succinate/naproxen sodium, naratriptan HCl, Comparator: Rizatriptan.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/axs-07.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

AXS-07 — Competitive Intelligence Brief

AXS-07 (AXS-07) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Triptan combination / 5-HT1B/1D receptor agonist. Area: Neurology.

phase 3 Triptan combination / 5-HT1B/1D receptor agonist 5-HT1B receptor, 5-HT1D receptor Neurology Small molecule Live · refreshed every 30 min

Target snapshot

AXS-07 (AXS-07) — Axsome Therapeutics, Inc.. AXS-07 is a combination of melitracen (a tricyclic compound) and rizatriptan that works synergistically to treat acute migraine by enhancing serotonergic activity and providing rapid symptom relief.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AXS-07 TARGET	AXS-07	Axsome Therapeutics, Inc.	phase 3	Triptan combination / 5-HT1B/1D receptor agonist	5-HT1B receptor, 5-HT1D receptor
Sumatriptan Succinate Oral Tablet	Sumatriptan Succinate Oral Tablet	Damanhour Teaching Hospital	marketed	Triptan (5-HT1B/1D receptor agonist)	5-HT1B receptor, 5-HT1D receptor
Migranal nasal spray at 1 hour	Migranal nasal spray at 1 hour	Thomas Jefferson University	marketed	Ergot alkaloid; serotonin receptor agonist	5-HT1B receptor, 5-HT1D receptor
Migranal nasal spray at 4 hour	Migranal nasal spray at 4 hour	Thomas Jefferson University	marketed	Ergot alkaloid; 5-HT1B/1D receptor agonist	5-HT1B receptor, 5-HT1D receptor
sumatriptan succinate/naproxen sodium	sumatriptan succinate/naproxen sodium	GlaxoSmithKline	marketed	5-HT1B/1D receptor agonist combined with NSAID	5-HT1B receptor, 5-HT1D receptor, COX-1, COX-2
naratriptan HCl	naratriptan HCl	Cady, Roger, M.D.	marketed	Triptan (5-HT1B/1D receptor agonist)	5-HT1B receptor, 5-HT1D receptor
Comparator: Rizatriptan	Comparator: Rizatriptan	Organon and Co	phase 3	Triptan (5-HT1B/1D receptor agonist)	5-HT1B receptor, 5-HT1D receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Triptan combination / 5-HT1B/1D receptor agonist class)

Axsome Therapeutics, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AXS-07 — Competitive Intelligence Brief. https://druglandscape.com/ci/axs-07. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab